Among patients with Ph-negative ALL, intensified therapy for those with IKZF1 deletions was associated with an 11% cumulative incidence of relapse (CIR) and a 44% reduction in 5-year CIR compared to the previous trial (MS2003) [84]. Here, IKZF1 is linked to acute lymphoblastic leukemia.